Loading clinical trials...
Loading clinical trials...
A Phase 1b Trial of Mavorixafor, an Oral CXCR4 Antagonist, in Combination With Ibrutinib in Patients With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
Conditions
Interventions
Mavorixafor
Ibrutinib
Locations
5
United States
Colorado Blood Cancer Institute
Denver, Colorado, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Mass General Hospital Cancer Center
Boston, Massachusetts, United States
MD Anderson Cancer Center
Houston, Texas, United States
University of Athens
Athens, Greece
Start Date
April 30, 2020
Primary Completion Date
October 31, 2022
Completion Date
October 31, 2022
Last Updated
August 27, 2024
NCT01647971
NCT01046006
NCT01125293
NCT00936611
NCT02363439
NCT00142116
Lead Sponsor
X4 Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions